Global Pediatric Drug Development Collaboration: Part One

Overview


Global-Pediatric-Drug-Development-Collaboration-Part-One.jpg

The pharmaceutical industry is unlike any other industry in that the products manufactured can dramatically improve, and even save, lives. This is especially the case when it comes to children. Although pediatric patients comprise a smaller population of pharmaceutical consumers, they have a greater need for products given the paucity of treatment options specifically for them. This two-part paper discusses the need for collaboration across the industry to ensure children get the medicines they need. Download to read Part One or click here to read Part Two

This content is provided by PRA Health Sciences, and any views and opinions expressed do not necessarily reflect those of Outsourcing-Pharma.com

Download Now


Latest Content

Related Resources

Global Pediatric Drug Development Collaboration: Part Two

Global Pediatric Drug Development Collaboration: Part Two

Content provided by PRA Health Sciences

White Paper

70% of medicines given to children have never been studied in pediatric populations. Children who need treatments represent a relatively small population. This alone presents unique challenges for pediatric drug development. Since the 1990s, authorities...

Supplier Info Centre

PRA-Health-Sciences.png

For more product information visit PRA Health Sciences.